| Literature DB >> 24669215 |
Jinlin Yang1, Rui Wang1, Wenyan Zhang2, Wen Zhuang3, Mojin Wang3, Chengwei Tang1.
Abstract
The present study was undertaken to clarify the association of the clinicopathological features of hepatoid adenocarcinoma (HAC) in the stomach, a special kind of carcinoma that histologically resembled hepatocellular carcinoma (HCC) and is characterized by large amounts of α -fetoprotein (AFP) in serum, with the clinical prognosis. We collected the data of the clinicopathological features and the follow-up information from a total of 31 HACs from January 2005 to December 2012 in our hospital. High lymphatic (54.8%) and distant (25.8%) metastasis rates before surgery, large proportion of advanced HACs (71.0%) at admission, short median overall survival time (6 months), and low three-year survival rate (22.6%) suggested that HAC in the stomach was an aggressive disease, resulting in a poor prognosis. And pTNM stages, immunohistochemical staining of AFP, CEA, CK7, and CK20 had statistically relation with the survival as the independent risk factors, P < 0.05. Therefore, early and clear differentiation of HAC from cancerous or noncancerous conditions with AFP elevation and assessment of high risk patients by histopathology may improve the clinical prognosis.Entities:
Year: 2014 PMID: 24669215 PMCID: PMC3942340 DOI: 10.1155/2014/140587
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Prognostic factors related to prognosis by the Kaplan-Meier method.
| Clinicopathological factors | Total number | Mean time (month) |
| |||
|---|---|---|---|---|---|---|
| Estimate | Std. error | 95% CI | ||||
| Lower | Upper | |||||
| Gender | ||||||
| Female | 10 | 20.700 | 6.002 | 8.896 | 32.504 | 0.384 |
| Male | 21 | 12.000 | 2.963 | 6.192 | 17.808 | |
| Elevation of serum AFP | ||||||
| Yes | 27 | 15.704 | 3.201 | 9.429 | 21.978 | 0.467 |
| No | 4 | 8.750 | 2.926 | 3.015 | 14.485 | |
| Location of cancer | ||||||
| Eso-cardia | 10 | 16.800 | 5.083 | 6.837 | 26.763 | 0.975 |
| Body | 12 | 12.417 | 4.485 | 3.627 | 21.207 | |
| Antrum | 9 | 15.778 | 5.734 | 4.538 | 27.017 | |
| pTNM stages | ||||||
| I | 7 | 36.714 | 5.838 | 25.272 | 48.157 | 0.000 |
| II | 6 | 20.333 | 3.853 | 12.782 | 27.885 | |
| III | 10 | 5.800 | 0.867 | 4.101 | 7.499 | |
| IV | 8 | 2.750 | 0.250 | 2.260 | 3.240 | |
| AFP IHC | ||||||
| Yes | 28 | 14.679 | 2.902 | 8.991 | 20.366 | 0.037 |
| No | 3 | 37.000 | 13.503 | 0.000 | 42.466 | |
| Hep Par 1 IHC | ||||||
| Yes | 8 | 8.625 | 4.931 | 0.000 | 18.291 | 0.105 |
| No | 23 | 16.957 | 3.354 | 10.383 | 23.530 | |
| CEA IHC | ||||||
| Yes | 19 | 8.737 | 2.867 | 3.117 | 14.357 | 0.008 |
| No | 12 | 24.417 | 4.642 | 15.317 | 33.516 | |
| CK20 IHC | ||||||
| Yes | 11 | 3.444 | 0.556 | 2.356 | 4.533 | 0.000 |
| No | 20 | 19.455 | 3.545 | 12.507 | 26.402 | |
| CK7 IHC | ||||||
| Yes | 11 | 3.333 | 0.715 | 1.932 | 4.735 | 0.000 |
| No | 20 | 17.560 | 3.284 | 11.124 | 23.996 | |
| AE1/AE3 IHC | ||||||
| Yes | 24 | 13.571 | 4.613 | 4.530 | 22.613 | 0.786 |
| No | 7 | 15.167 | 3.447 | 8.411 | 21.922 | |
Prognostic factors related to prognosis by Cox multivariate regression analysis.
| Clinicopathological factors |
| RR | 95% CI | |
|---|---|---|---|---|
| Lower | Upper | |||
| pTNM stages | 0.000 | 17.649 | 3.590 | 7.202 |
| AFP IHC | 0.023 | 0.371 | 0.173 | 1.263 |
| CEA IHC | 0.044 | 0.268 | 0.074 | 0.965 |
| CK20 IHC | 0.014 | 14.063 | 1.703 | 16.108 |
| CK7 IHC | 0.004 | 0.029 | 0.003 | 0.333 |
Figure 1The overall survival of HACs.